West Pharmaceutical Services, Inc. (NYSE:WST) is a leading provider of innovative solutions for injectable drug administration. The company specializes in the design and manufacture of packaging components and delivery systems for injectable drugs and healthcare products. It operates in two main segments: Proprietary Products and Contract-Manufactured Products. Competitors include companies like AptarGroup and Gerresheimer.
On October 23, 2025, Daniel Markowitz from Evercore ISI set a new price target for WST at $390, a 26.1% increase from its trading price of $309.28, as highlighted by TheFly. This optimistic outlook follows a strong third-quarter performance, where WST reported adjusted earnings per share (EPS) of $1.96, surpassing the Zacks Consensus Estimate by 17.4%.
The company's quarterly revenues reached $804.6 million, reflecting a 7.7% year-over-year growth. This growth was driven by a 7.7% increase in sales of Proprietary Products, with High-Value Product components experiencing a significant 16.3% growth. The strong demand for GLP-1 products and increased HVP conversion contributed to this success.
West Pharmaceutical has raised its full-year EPS outlook to a range of $7.06 to $7.11, citing strong demand and favorable foreign exchange conditions. The company's market capitalization stands at approximately $22.35 billion, with a trading volume of 1,334,906 shares. The stock has experienced a 12.22% rise, trading at $310.85, with a daily fluctuation between $300 and $322.34.
